Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Amur Minerals ( (GB:CRTX) ) has shared an announcement.
CRISM Therapeutics has announced the resignation of Dr Nermeen Varawalla from its Board of Directors, where she had served as Non-Executive Chair since the company’s admission to AIM in May 2024. Her departure follows an earlier decision in October 2025 to step back from the role as the company advances its clinical and commercial plans.
Andrew Webb will continue as Executive Chair on an interim basis while CRISM undertakes a search for a new Chair with skills aligned to its forthcoming phase 2 clinical trial and commercialisation strategy. The company has reassigned committee leadership roles, with Independent Non-Executive Director Gerry Beaney now chairing the Remuneration Committee, signalling an effort to maintain governance continuity during the leadership transition.
The most recent analyst rating on (GB:CRTX) stock is a Hold with a £12.50 price target. To see the full list of analyst forecasts on Amur Minerals stock, see the GB:CRTX Stock Forecast page.
Spark’s Take on CRTX Stock
According to Spark, TipRanks’ AI Analyst, CRTX is a Neutral.
The score is held back primarily by weak financial fundamentals (very small revenue with ongoing losses and negative free cash flow), despite improved loss/cash-burn trends and a debt-free balance sheet. Technically, momentum is positive, but the very high RSI suggests near-term overextension. Valuation remains unattractive/unclear due to negative earnings and no indicated dividend support.
To see Spark’s full report on CRTX stock, click here.
More about Amur Minerals
CRISM Therapeutics Corporation is a UK-based clinical-stage drug delivery company focused on improving cancer treatment for solid tumours through localised and sustained chemotherapy delivery. Its lead product, ChemoSeed, is an implantable technology designed to deliver high concentrations of chemotherapy directly into tumours or surgical resection margins, including applications in glioblastoma where it can bypass the blood-brain barrier.
Average Trading Volume: 349,985
Technical Sentiment Signal: Hold
Current Market Cap: £6.08M
Find detailed analytics on CRTX stock on TipRanks’ Stock Analysis page.